HEART GENOMICS, LLC
MIAMI BEACH, FLORIDA

Heart Genomics, LLC, based in Miami Beach, Florida, is a pioneering biotechnology company dedicated to the commercialization of genomic-based diagnostic tests for heart failure patients. Founded by Paul T. Lehr as manager, Heat Genomics has evolved from over two decades of extensive research at Johns Hopkins University School of Medicine and the University of Miami’s Interdisciplinary Stem Cell Institute. Leveraging technologies stemming from the Human Genome Project and proprietary gene signatures developed by Co-Founder Joshua M. Hare, MD, this company offers novel biomarkers through its diagnostic tools, specifically HeartGen5YP and HeartGenMYO. These expression profiling tests utilize state-of-the-art human gene expression profiles to provide highly accurate diagnoses and prognoses for heart failure patients. Heart Genomics plans to generate revenue by offering these sophisticated clinical laboratory tests on a fee basis nationwide. The tests analyze expression profiles from either heart tissue or, following further validation, blood samples, delivering quantitative gene expression profile scores to physicians. The company aims to be a leader in the molecular diagnostics market through its commitment to personalized and individualized genetic analysis of patient samples. Heart Genomics' innovative approach not only enhances diagnostic precision but also empowers patients and physicians to make more informed treatment decisions. As a Florida incorporated entity (Filed Number: L10000132225), Heart Genomics is dedicated to advancing non-invasive genomic diagnostics, with an annual report last filed on January 15, 2024.